GLP-1 receptor agonists have reshaped how clinicians treat both type 2 diabetes and obesity. And two names now dominate the conversation: Mounjaro (tirzepatide) and Ozempic (semaglutide). Both are weekly subcutaneous injections that suppress appetite. They have produced weight-loss numbers that were almost unthinkable a decade ago. Yet they are not interchangeable. They act on different receptor pathways, come from different manufacturers, and carry different FDA indications.
Understanding how Mounjaro and Ozempic actually work matters whether you are a patient weighing options or a clinician counseling one. This article breaks down mechanism, efficacy, safety, and cost to inform that conversation. For broader context, the FDA’s overview of GLP-1 receptor agonists is a useful starting point.
What Is Mounjaro (Tirzepatide)?
Mounjaro is the brand name for tirzepatide, manufactured by Eli Lilly and approved by the FDA in May 2022 for adults with type 2 diabetes as an adjunct to diet and exercise. It is the first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dosing starts at 2.5 mg once weekly and titrates in 2.5 mg increments up to a maximum of 15 mg.
Mounjaro is not FDA-approved for obesity, though prescribers commonly use it off-label for weight loss. Lilly’s SURMOUNT program is investigating a higher-dose obesity indication under the Zepbound brand. Full FDA prescribing information for Mounjaro is available online.
What Is Ozempic (Semaglutide)?
Ozempic is the brand name for semaglutide, a Novo Nordisk product approved by the FDA in 2017 for type 2 diabetes. It is a long-acting GLP-1 receptor agonist delivered as a once-weekly subcutaneous injection at maintenance doses of 0.5 mg, 1 mg, or 2 mg.
Like Mounjaro, Ozempic is not FDA-approved for weight loss — that indication belongs to Wegovy, which is the same molecule (semaglutide) dosed up to 2.4 mg for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Patients often ask whether Ozempic and Wegovy are identical; pharmacologically yes, but the FDA label, dosing, and insurance coverage differ.
Mechanism of Action: Dual vs Single Agonism
Both drugs mimic or enhance the action of incretin hormones — gut-derived signals that tell the pancreas to release insulin after eating. GLP-1, the target of Ozempic, slows gastric emptying, reduces glucagon secretion, and acts on the brain’s appetite centers to produce satiety. Patients describe feeling full faster and staying full longer.
Mounjaro takes a broader approach. Tirzepatide is a synthetic peptide that activates both the GLP-1 receptor and the GIP receptor. GIP contributes additional insulin secretion in a glucose-dependent manner and is thought to improve adipose tissue metabolism and reduce food intake through pathways that complement GLP-1.
The dual mechanism is the central reason Mounjaro’s SURMOUNT-1 trial posted larger weight-loss numbers than any GLP-1-only agent before it, a finding published in the New England Journal of Medicine. Researchers hypothesize that GIP activity may also buffer some GI side effects that limit Ozempic titration, though this remains under investigation. The mechanism distinction is not academic — it appears to translate directly into the efficacy gap discussed below.
Effectiveness in Weight Loss: Trial Evidence
The two pivotal trials patients compare are SURMOUNT-1 for tirzepatide and STEP 1 for semaglutide 2.4 mg (Wegovy). They were not head-to-head, so comparisons are indirect, but the numbers are striking.
In SURMOUNT-1, published in NEJM in 2022, adults with obesity or overweight randomized to tirzepatide 15 mg lost an average of 22.5% of body weight over 72 weeks; 91% of participants achieved at least 5% weight loss, and 36% achieved at least 25%. Lower doses (5 mg, 10 mg) produced 15–20% losses. The full SURMOUNT-1 publication is open-access.
In STEP 1, published in NEJM in 2021, adults with obesity on semaglutide 2.4 mg lost an average of 14.9% over 68 weeks; 86% reached the 5% threshold and 32% reached 20%. The STEP 1 publication remains the reference standard for GLP-1-only weight loss evidence.
Both agents outperform older anti-obesity medications by a wide margin. For patients, the practical takeaway: tirzepatide at maximal dose produces roughly 7–8 percentage points more weight loss than semaglutide 2.4 mg in indirect comparison, but individual response varies widely and high-quality head-to-head data is still emerging.
Side Effects and Safety Profile
Both drugs share a similar gastrointestinal side-effect profile because both activate GLP-1 receptors. Nausea, diarrhea, constipation, vomiting, and abdominal pain are the most common complaints, typically worst during dose escalation and often improving after four to six weeks at maintenance dose.
The FDA has issued a boxed warning for both drugs regarding thyroid C-cell tumors observed in rodent studies; both are contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.
- Other notable risks include:
- Pancreatitis
- Gallbladder disease
- Kidney injury (often secondary to dehydration from vomiting)
- Hypoglycemia when combined with insulin or sulfonylureas.
Reports of suicidal ideation prompted an FDA review; the agency’s 2024 preliminary evaluation found no consistent association but recommended continued monitoring.
Patients should not start either drug without disclosing prior pancreatitis, thyroid disease, or eating-disorder history.
Cost, Access, and Insurance
Both Mounjaro and Ozempic carry list prices near or above $1,000 per month, although out-of-pocket costs vary widely with insurance, manufacturer savings cards, and pharmacy benefit design. Medicare Part D has historically excluded weight-loss coverage, though CMS recently finalized a rule expanding coverage of anti-obesity medications for Medicare beneficiaries starting in 2025.
Both drugs have faced periodic shortages, with Ozempic in particular experiencing supply constraints that pushed some patients to compounded versions — products the FDA has warned are not FDA-approved. Wegovy (semaglutide for weight loss) and Zepbound (tirzepatide for weight loss) are the on-label brands if obesity, not diabetes, is the treatment target.
Which Medication Is Right for You?
There is no universally “better” drug. Choice depends on the FDA-approved indication (diabetes versus obesity), prior response to GLP-1 agents, side-effect tolerance, insurance coverage, supply availability, and your prescriber’s clinical judgment. Head-to-head data is still maturing, and off-label use of either agent for weight loss — particularly compounded versions — carries distinct risks.
The strongest evidence currently supports tirzepatide producing larger weight loss in adults with obesity, but a clinician’s individualized assessment matters more than any blog headline. Bring your full medication history, insurance formulary, and weight-loss goals to your appointment.
Frequently Asked Questions
Is Mounjaro more effective than Ozempic for weight loss?
Indirect trial comparison suggests tirzepatide (Mounjaro) produces more weight loss than semaglutide (Ozempic) at equivalent dosing — roughly 22.5% versus 14.9% in pivotal trials. A formal head-to-head trial is still ongoing, so individual results vary.
Can I switch from Ozempic to Mounjaro?
Yes, under a clinician’s supervision. Patients often transition to a low starting dose of tirzepatide and titrate upward, monitoring for nausea or vomiting. Do not switch without medical guidance.
Are Mounjaro and Ozempic FDA-approved for weight loss?
No. Mounjaro is approved for type 2 diabetes; Ozempic is approved for type 2 diabetes. The semaglutide brand Wegovy and tirzepatide brand Zepbound carry the FDA-approved obesity indications.
What are the most common side effects of Mounjaro and Ozempic?
Nausea, diarrhea, constipation, vomiting, and abdominal pain top both lists. Symptoms are typically worst during dose escalation. Both drugs carry a boxed warning for thyroid C-cell tumors.
How long should you take Mounjaro or Ozempic?
Both are intended for chronic use. Weight regain after discontinuation is common; the STEP 1 extension trial showed substantial regain one year off semaglutide. Discuss a long-term plan with your provider.